[HTML][HTML] Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
DR Camidge, HR Kim, MJ Ahn, JCH Yang… - … England Journal of …, 2018 - Mass Medical Soc
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
DR Camidge, HR Kim, MJ Ahn, JC Yang, JY Han… - 2018 - christie.openrepository.com
BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
DR Camidge, HR Kim, MJ Ahn, JCH Yang… - New England Journal …, 2018 - cir.nii.ac.jp
Brigatinib versus Crizotinib in <i>ALK</i>-Positive Non–Small-Cell Lung Cancer | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
DR Camidge, HR Kim, MJ Ahn, JC Yang… - The New England …, 2018 - mpgjournal.mpg.es
BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han… - 2018 - repository.icr.ac.uk
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
DR Camidge, HR Kim, MJ Ahn… - The New England …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
[PDF][PDF] Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han… - 2018 - core.ac.uk
BACKGROUND Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
has robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
has robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
DR Camidge, HR Kim, MJ Ahn… - New England Journal …, 2018 - s-space.snu.ac.kr
BACKGROUND Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
DR Camidge, HR Kim, MJ Ahn, JC Yang… - The New England …, 2018 - europepmc.org
Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
DR Camidge, HR Kim, MJ Ahn… - … England Journal of …, 2018 - snucm.elsevierpure.com
BACKGROUND Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …
has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is …